Oct 30 (Reuters) - Reviva Pharmaceuticals Holdings said on Monday its experimental drug to treat adults with schizophrenia met the main goal of a late-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Savio D'Souza)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.71 USD | 0.00% | -20.09% | -66.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.80% | 4.77Cr | |
+33.37% | 4.95TCr | |
+1.55% | 4.26TCr | |
+49.11% | 4.25TCr | |
-4.22% | 2.91TCr | |
+11.57% | 2.66TCr | |
-21.00% | 1.86TCr | |
+7.36% | 1.32TCr | |
+28.30% | 1.25TCr | |
+23.80% | 1.21TCr |
- Stock Market
- Equities
- RVPH Stock
- News Reviva Pharmaceuticals Holdings, Inc.
- Reviva Pharma's schizophrenia drug succeeds in late-stage study